Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II randomized double-blind controlled study of SNA02-48 injection for tetanus prevention in adults
CTR20251476Phase 2Active
- Sponsor
- Sino Biopharmaceutical Limited
- Start
- Apr 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of SNA02-48 in Tetanus, sponsored by Sino Biopharmaceutical Limited. Started Apr 2025; status: active.
02
Drugs
SNA02-48
03
Conditions
Tetanus
Beyond the preview
Go deeper on CTR20251476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251476.